SLN124 Granted Orphan Drug Designation by EMA for the Treatment of β-Thalassemia
London, Jan. 15 (Korea Bizwire) – Silence Therapeutics, PLC (LON: SLN) (“Silence” or “the Company”) a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, announces that its lead medicine candidate SLN124 has been granted Orphan Drug Designation by the Committee for Orphan Medicinal Products (COMP), the [...]